ArticleOchsner journal1999
Tobacco smoke: chemical carcinogenesis and genetic lesions.
Article in Ochsner journal, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 3 citations in OpenAlex.
- Tobacco Smoke Condensate Induces Morphologic Changes in Human Papillomavirus-Positive Cervical Epithelial Cells Consistent with Epithelial to Mesenchymal Transition (EMT) with Activation of Receptor Tyrosine Kinases and Regulation ofInternational journal of molecular sciences · 2024Article
- Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer.Molecular cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the primary cause of cancer-related death in the United States and smoking is the major contributing factor. An amazing array of carcinogenic and precarcinogenic agents has been identified in cigarette smoke. This review addresses the mechanisms by which some of the predominant lung carcinogens mutagenize DNA and explores some of the pivotal genes that are both susceptible to mutagenesis and contribute to the process of tumorigenesis and carcinogenesis. In addition, genes, gene products, and genetic polymorphisms, which curtail the processes leading to carcinogenesis, are discussed. The availability of clinically serviceable methods for analysis of genetic changes that can contribute to lung cancer is imperative to the development of timely, accurate, and cost-effective diagnostic and prognostic tests.A more thorough understanding of the step-wise conversion of precarcinogens to carcinogens, binding of carcinogens to DNA, mutation of DNA, DNA repair, and cellular destruction of carcinogens should contribute to the design of drugs that can modify these processes. In addition, introduction of genes (such as the p53 tumor supressor gene) into susceptible lung cells may impede carcinogenesis. Early stage clinical trials for the treatment of lung cancer using this and other genes are presently underway.
Identifiers
21845130PMC3145448W1655744316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.